This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gascon, G. G. Search for Related Content PubMed PubMed Citation Articles by Gascon, G. G. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Social Bookmarking                   What's this?

Randomized Treatment Study of Inosiplex Versus Combined Inosiplex and Intraventricular Interferon- in Subacute Sclerosing Panencephalitis (SSPE): International Multicenter Study

Department of Neuroscience, MBC J-76, King Faisal Specialist Hospital and Research Center, PO Box 40047, Jeddah 21499, Saudi Arabia, generoso_gascon{at}brown.edu

The efficacy of oral inosiplex alone (group A) versus combined treatment of inosiplex (Isoprinosine) and intraventricular interferon-2b (Intron A) (group B) in patients with subacute sclerosing panencephalitis (SSPE) was compared. One hundred and twenty-one patients who met the diagnostic criteria for subacute sclerosing panencephalitis and presented at stage 2 or less were randomized into group A or B. Data were analyzable on 67 patients who met the inclusion criteria and adhered to the protocol. The inosiplex dosage was 100 mg/kg/day to a maximum of 3 g/day, taken orally in three divided doses for 6 months. Interferon-2b started with 100,000 U/m² and escalated to 1,000,000 U/m² over 5 inpatient days and then 1,000,000 U/m2 twice a week for 6 months. Neurologic status was rated by the Neurological Disability Index, Brief Assessment Examination, and stages. Kaplan-Meier survival rates were not statistically significant between group A and group B (log-rank test X² = .1374, P = .7109). In longitudinal morbidity analyses, regression results were fitted to three outcome measures: the Neurological Disability Index, the Brief Assessment Examination, and stage. Group medians of the estimated regression slopes were then compared using the Wilcoxon rank-sum test. There was no statistically significant difference between the two groups on any of these three measures. Morbidity comparisons of clinical classification of outcomes (improvement, stabilization, worsening after treatment stopped, deterioration) also showed no statistically signficant difference between groups. There were no statistically significant differences between the two treatment groups on any efficacy measure. However, the observed rates of satisfactory outcome (stabilization, improvement) of 34% in group A and 35% in group B were higher than the spontaneous remission rates of 5 to 10% reported in the literature, suggesting that treatment was superior to no treatment. (J Child Neurol 2003;18:819-827).

Journal of Child Neurology, Vol. 18, No. 12, 819-827 (2003)
DOI: 10.1177/088307380301801201


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				D. Becker, A. Patel, B. W. Abou-Khalil, and J. E. Pina-Garza Successful Treatment of Encephalopathy and Myoclonus with Levetiracetam in a Case of Subacute Sclerosing Panencephalitis J Child Neurol, June 1, 2009; 24(6): 763 - 767. [Abstract] [PDF]

				G. G. Gascon Autobiography: A Clinician's Odyssey J Child Neurol, March 1, 2009; 24(3): 379 - 392. [PDF]

				M. B.A. Oldstone, S. Dales, A. Tishon, H. Lewicki, and L. Martin A role for dual viral hits in causation of subacute sclerosing panencephalitis J. Exp. Med., November 7, 2005; 202(9): 1185 - 1190. [Abstract] [Full Text] [PDF]

				A Hassan, O Lily, M Johnson, and A Al-Din Adult onset SSPE: experiences in West Yorkshire over a 12 month period J. Neurol. Neurosurg. Psychiatry, September 1, 2005; 76(9): 1310 - 1311. [Full Text] [PDF]

				J. G. Millichap The Changing Character of Subacute Sclerosing Panencephalitis AAP Grand Rounds, February 1, 2005; 13(2): 18 - 18. [Full Text] [PDF]

				I. Wirguin, T. Vander, T. Brenner, O. Abramsky, I. Steiner, E. Matsubara, T. Kurata, M. Yokoyama, I. Nagano, M. Shoji, et al. Improvement of SSPE by intrathecal infusion of {alpha}-IFN Neurology, January 25, 2005; 64(2): 402 - 402. [Full Text] [PDF]

				J. F. Bale Jr. Subacute sclerosing panencephalitis: A preventable disease that needs to be prevented Neurology, October 26, 2004; 63(8): 1352 - 1353. [Full Text] [PDF]

				S. Honarmand, C. A. Glaser, E. Chow, J. J. Sejvar, C. P. Preas, G. C. Cosentino, H. T. Hutchison, and W. J. Bellini Subacute sclerosing panencephalitis in the differential diagnosis of encephalitis Neurology, October 26, 2004; 63(8): 1489 - 1493. [Abstract] [Full Text] [PDF]